13 June 2019

Scancell issues new shares to Vulpes Life Sciences Fund

Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £3.89m by the issue of new ordinary shares to Vulpes Life Sciences Fund.

Vulpes was founded in 2011 by Stephen Diggle, co-founder and former Managing Partner of Artradis Fund Management. Vulpes is designed to replicate a family office structure and enable outside co-investment in a range of strategies that seek to produce real capital appreciation and income by concentrating on a small number of compelling investment opportunities.

Co-founder Martin Diggle commented “Vulpes has been conducting scientific and commercial due diligence on Scancell for a considerable period of time. We have concluded the company's unique and innovative approach to fighting cancer is compelling and under-appreciated. At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly."

LGB is advising Scancell on the development of its investment proposition and its engagement with investors.

Recent Articles

26 May 2020

BoE: Negative interest rates not ruled out

Andrew Boyle, CEO of LGB & Co. Limited, contributed to an article for Mortgage Introducer Bank of England Governor Andrew Bailey's refusal to rule out the prospect of negative interest rates.

 

Read more

News & Insights

4 May 2020

Small cap movers: Coronavirus crisis shines a light on small-cap pharma

Ivan Sedgwick, Investments Director at LGB & Co. Limited, contributed to an article for ProActive Investors on small-cap pharmaceutical companies in the Coronavirus limelight.

Read more

News & Insights

30 April 2020

What impact is COVID-19 having on stocks?

Ivan Sedgwick, Director of Investments at LGB & Co, spoke to BLM to find out about the current outlook for the AIM market.

 

Read more

News & Insights